synergistic merger and acquisition opportunities to strengthen its
pipeline and/or financial position.
-- Cash and cash equivalents as of October 1, 2008 were approximately
$5.9 million, which after accounting for the company's liabilities and
other commitments, results in approximately $2.5 million. This cash
is sufficient to support operations until second quarter 2009.
About Nventa Corporation:
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by HPV. The company is publicly traded on the Toronto Stock Exchange under the symbol "NVN". For more information about Nventa, please visit http://www.nventacorp.com.
This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include statements regarding the company's future plans, objectives, performance, growth or the company's underlying assumptions. The words "may", "would", "will", "expect," "intend", "plan", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only expectations, and that the company's actual future results or performance may be materially different.
Forward-looking statements or information in this press release
include, but are not limited to, statements or information concerning: our
planned corporate restructuring and the affect it will have on our
financial resources; plans to seek strategic alliances and our subsequent
ability to realize the greatest value for our progr
|SOURCE Nventa Corporation|
Copyright©2008 PR Newswire.
All rights reserved